Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Portfolio Pulse from
Bluebird Bio, a gene therapy company, is being sold to private equity firms Carlyle and SK Capital for approximately $30 million. The company produces three gene therapies: Zynteglo, Lyfgenia, and Skysona.
February 21, 2025 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bluebird Bio is being acquired by Carlyle and SK Capital for $30 million. This marks a significant change for the company, which has faced challenges in the gene therapy market.
The acquisition by Carlyle and SK Capital is a major event for Bluebird Bio, indicating a shift in strategy and potential stabilization after tough times. This could lead to a positive short-term impact on the stock price as investors react to the acquisition news.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100